Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Clinical Cancer Drugs
  4. Volume 10, Issue 1
  5. Article
Volume 10, Issue 1
  • ISSN: 2212-697X
  • E-ISSN: 2212-6988

Abstract

Colorectal cancer (CRC) is the third most commonly occurring cancer and the second leading cause of cancer-related deaths worldwide. Conventional treatments for CRC, such as surgery, chemotherapy, and radiotherapy, have long been the primary options for patients. However, their therapeutic success rates are relatively low, necessitating the development of novel technologies. The prognosis for metastatic CRC patients has historically been unsatisfactory. Recent efforts have focused on advancing our understanding of CRC progression, leading to improvements in CRC management and the identification of key regulatory genes involved in colorectal cancer. The complex interaction between the tumor microenvironment and CRC progression has unveiled new immunotherapy targets, including immune checkpoint inhibitors and CAR T-cell-based therapies. Additionally, novel approaches targeting cell signaling pathways that promote cell proliferation and metastasis in CRC show great potential for improving patient outcomes. This article explores and summarizes the epidemiology, carcinogenesis, and stages of CRC, as well as current treatment strategies and drug targets. It highlights the molecular mechanisms underlying tumorigenesis and progression in colorectal cancer.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccand/10.2174/012212697X308365240529100442
2024-07-11
2025-03-27

  • From This Site

    /content/journals/ccand/10.2174/012212697X308365240529100442
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HounnouG. DestrieuxC. DesmeJ. BertrandP. VelutS. Anatomical study of the length of the human intestine.Surg. Radiol. Anat.200224529029410.1007/s00276‑002‑0057‑y12497219
     [Google Scholar]
  2. MarkowitzS.D. DawsonD.M. WillisJ. WillsonJ.K.V. Focus on colon cancer.Cancer Cell20021323323610.1016/S1535‑6108(02)00053‑312086859
     [Google Scholar]
  3. MarkowitzS.D. BertagnolliM.M. Molecular origins of cancer: Molecular basis of colorectal cancer.N. Engl. J. Med.2009361252449246010.1056/NEJMra080458820018966
     [Google Scholar]
  4. KanthanR. SengerJ.L. KanthanS.C. Molecular events in primary and metastatic colorectal carcinoma: A review.Pathol. Res. Int.2012201211410.1155/2012/59749722997602
     [Google Scholar]
  5. BujandaL. CosmeA. GilI. Arenas-MiraveJ.I. Malignant colorectal polyps.World J. Gastroenterol.201016253103311110.3748/wjg.v16.i25.310320593495
     [Google Scholar]
  6. ShussmanN. WexnerS.D. Colorectal polyps and polyposis syndromes.Gastroenterol. Rep. (Oxf.)20142111510.1093/gastro/got04124760231
     [Google Scholar]
  7. BosmanF.T. CarneiroF. WHO Classification of Tumours of the Digestive System.Lyon, FranceIARC Publications2010
     [Google Scholar]
  8. AminM.B. EdgeS. GreeneF. AJCC Cancer Staging Manual.New YorkSpringer International Publishing2017
     [Google Scholar]
  9. BaxterN.N. GuillemJ.G. Colorectal Cancer: Epidemiology, Etiology, and Molecular Basis The ASCRS Textbook of Colon and Rectal Surgery.New York, NYSpringer200733535210.1007/978‑0‑387‑36374‑5_23
     [Google Scholar]
  10. CherryL.M. The genetic etiology of familial and nonfamilial colorectal cancer.Proc. Bayl. Univ. Med. Cent.201124213914110.1080/08998280.2011.1192870221566761
     [Google Scholar]
  11. DuanB ZhaoY BaiJ Colorectal cancer: An overview. Gastrointestinal Cancers.Brisbane (AU): Exon Publications2022
     [Google Scholar]
  12. TomaM. BeluşicăL. StavarachiM. Rating the environmental and genetic risk factors for colorectal cancer.J. Med. Life20125Spec Issue15215931803304
     [Google Scholar]
  13. CenterM.M. JemalA. SmithR.A. WardE. Worldwide variations in colorectal cancer.CA Cancer J. Clin.200959636637810.3322/caac.2003819897840
     [Google Scholar]
  14. SandhuM.S. WhiteI.R. McPhersonK. Systematic review of the prospective cohort studies on meat consumption and colorectal cancer risk: A meta-analytical approach.Cancer Epidemiol. Biomarkers Prev.200110543944611352852
     [Google Scholar]
  15. SandlerR.S. Epidemiology and risk factors for colorectal cancer.Gastroenterol. Clin. North Am.199625471773510.1016/S0889‑8553(05)70271‑58960889
     [Google Scholar]
  16. ChanA.T. GiovannucciE.L. Primary prevention of colorectal cancer.Gastroenterology2010138620292043.e1010.1053/j.gastro.2010.01.05720420944
     [Google Scholar]
  17. BoffettaP. HazeltonW.D. ChenY. Body mass, tobacco smoking, alcohol drinking and risk of cancer of the small intestine—a pooled analysis of over 500 000 subjects in the Asia Cohort Consortium.Ann. Oncol.20122371894189810.1093/annonc/mdr56222147734
     [Google Scholar]
  18. WanS. TangQ. FengD. HuZ. ShaoW. ChenY. Epidemiology characteristics of ethnic minority colorectal cancer in Yunnan in Southwestern China.Transl. Cancer Res.2020942692270010.21037/tcr.2020.02.6335117628
     [Google Scholar]
  19. BurtR.W. DiSarioJ.A. Cannon-AlbrightL. Genetics of colon cancer: Impact of inheritance on colon cancer risk.Annu. Rev. Med.19954637137910.1146/annurev.med.46.1.3717598472
     [Google Scholar]
  20. KastrinosF. SyngalS. Inherited colorectal cancer syndromes.Cancer J.201117640541510.1097/PPO.0b013e318237e40822157284
     [Google Scholar]
  21. Laurent-PuigP. AgostiniJ. MaleyK. [Colorectal oncogenesis]Bull Cancer (Paris)201097111311132110.1684/bdc.2010.121621115420
     [Google Scholar]
  22. ArmaghanyT. WilsonJ.D. ChuQ. MillsG. Genetic alterations in colorectal cancer.Gastrointest. Cancer Res.201251192722574233
     [Google Scholar]
  23. TariqK. TariqK. GhiasK. GhiasK. Colorectal cancer carcinogenesis: A review of mechanisms.Cancer Biol. Med.201613112013510.20892/j.issn.2095‑3941.2015.010327144067
     [Google Scholar]
  24. FearnheadN.S. WildingJ.L. BodmerW.F. Genetics of colorectal cancer: Hereditary aspects and overview of colorectal tumorigenesis.Br. Med. Bull.2002641274310.1093/bmb/64.1.2712421723
     [Google Scholar]
  25. NiederhuberJ.E. DorshowJ.H. KastanM.B. TepperJ.E. Abeloff’s Clinical Oncology.6th edAmsterdam, NetherlandsElsevier Health Sciences20202208
     [Google Scholar]
  26. CamposF.G. Logullo WaitzbergA.G. KissD.R. WaitzbergD.L. Habr-GamaA. Gama-RodriguesJ. Diet and colorectal cancer: Current evidence for etiology and prevention.Nutr. Hosp.2005201182515762416
     [Google Scholar]
  27. Ryan-HarshmanM. AldooriW. Diet and colorectal cancer: Review of the evidence.Fam Physician Med Fam Can200753111913192018000268
     [Google Scholar]
  28. HouN. HuoD. DignamJ.J. Prevention of colorectal cancer and dietary management.Chin Clin Oncol2013221325841493
     [Google Scholar]
  29. CubiellaJ. Marzo-CastillejoM. Mascort-RocaJ.J. Clinical practice guideline. Diagnosis and prevention of colorectal cancer. 2018 Update.Gastroenterol. Hepatol.201841958559610.1016/j.gastrohep.2018.07.01230245076
     [Google Scholar]
  30. RiihimäkiM. HemminkiA. SundquistJ. HemminkiK. Patterns of metastasis in colon and rectal cancer.Sci. Rep.2016612976510.1038/srep2976527416752
     [Google Scholar]
  31. American Association for Cancer Research. Spreading colon cancer can bypass lymph nodes.Cancer Discov.201779924925
     [Google Scholar]
  32. CastellsA. [Colorectal cancer screening].Gastroenterol. Hepatol.201538Suppl. 1647010.1016/S0210‑5705(15)30021‑226520198
     [Google Scholar]
  33. XuY. KongB. ShenK. Adenocarcinoma of the ascending colon in a 31-year-old pregnant woman.Medicine (Baltimore)20189751e1370710.1097/MD.000000000001370730572499
     [Google Scholar]
  34. IlgenfritzH.C. MathewsW.R. Carcinoid tumors of the gastro-intestinal tract.Ann. Surg.1955141680781810.1097/00000658‑195506000‑0000714377324
     [Google Scholar]
  35. National Cancer InstituteGastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version.2017Available From: https://www.cancer.gov/types/gi-neuroendocrine-tumors/patient/gi-neuroendocrine-treatment-pdq
    [Google Scholar]
  36. Ray-CoquardI. Le CesneA. MichalletV. BoukovinasI. RanchereD. Tumeurs stromales du tractus digestif: Actualités 2003.Bull Cancer (Paris)20039016976
     [Google Scholar]
  37. Le CesneA. BlayJ.Y. BuiB.N. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).Eur. J. Cancer20104681344135110.1016/j.ejca.2010.02.01420211560
     [Google Scholar]
  38. RomagueraJ. HagemeisterF.B. Lymphoma of the colon.Curr. Opin. Gastroenterol.2005211808415687889
     [Google Scholar]
  39. JonesJ.A. AvritscherE.B.C. CooksleyC.D. MicheletM. BekeleB.N. EltingL.S. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.Support. Care Cancer200614650551510.1007/s00520‑006‑0055‑416601950
     [Google Scholar]
  40. QuayleF LowneyJ. Colorectal Lymphoma.Clin Colon Rectal Surg20061920495310.1055/s‑2006‑94234420011310
     [Google Scholar]
  41. ThielsC.A. BergquistJ.R. KrajewskiA.C. Outcomes of primary colorectal sarcoma: A National Cancer Data Base (NCDB) Review.J. Gastrointest. Surg.201721356056810.1007/s11605‑016‑3347‑028097468
     [Google Scholar]
  42. CooperC.R. ScullyB.F. Lee-KongS. Colorectal sarcoma: More than a gastrointestinal stromal tumor.Transl. Gastroenterol. Hepatol.201834210.21037/tgh.2018.07.0530148227
     [Google Scholar]
  43. BrayF. FerlayJ. SoerjomataramI. SiegelR.L. TorreL.A. JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.201868639442410.3322/caac.2149230207593
     [Google Scholar]
  44. SiegelR.L. WagleN.S. CercekA. SmithR.A. JemalA. Colorectal cancer statistics, 2023.CA Cancer J. Clin.202373323325410.3322/caac.2177236856579
     [Google Scholar]
  45. SiegelR.L. MillerK.D. Goding SauerA. Colorectal cancer statistics, 2020.CA Cancer J. Clin.202070314516410.3322/caac.2160132133645
     [Google Scholar]
  46. SiegelR.L. FedewaS.A. AndersonW.F. Colorectal cancer incidence patterns in the United States, 1974–2013.J. Natl. Cancer Inst.2017109810910.1093/jnci/djw32228376186
     [Google Scholar]
  47. WolfA.M.D. FonthamE.T.H. ChurchT.R. Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society.CA Cancer J. Clin.201868425028110.3322/caac.2145729846947
     [Google Scholar]
  48. MathewA. BabyB. WangK. Colorectal cancer incidence in younger adults in India.Gut202069101899190010.1136/gutjnl‑2019‑32027131836611
     [Google Scholar]
  49. EdwardsB.K. WardE. KohlerB.A. Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates.Cancer2010116354457310.1002/cncr.2476019998273
     [Google Scholar]
  50. PhillipsK.A. LiangS.Y. LadabaumU. Trends in colonoscopy for colorectal cancer screening.Med. Care200745216016710.1097/01.mlr.0000246612.35245.2117224779
     [Google Scholar]
  51. SmithR.A. AndrewsK.S. BrooksD. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening.CA Cancer J. Clin.201868429731610.3322/caac.2144629846940
     [Google Scholar]
  52. AraghiM. SoerjomataramI. BardotA. Changes in colorectal cancer incidence in seven high-income countries: A population-based study.Lancet Gastroenterol. Hepatol.20194751151810.1016/S2468‑1253(19)30147‑531105047
     [Google Scholar]
  53. SiegelR.L. TorreL.A. SoerjomataramI. Global patterns and trends in colorectal cancer incidence in young adults.Gut201968122179218510.1136/gutjnl‑2019‑31951131488504
     [Google Scholar]
  54. VuikF.E.R. NieuwenburgS.A.V. BardouM. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years.Gut201968101820182610.1136/gutjnl‑2018‑31759231097539
     [Google Scholar]
  55. SauerA.G. SiegelR.L. JemalA. FedewaS.A. Updated review of prevalence of major risk factors and use of screening tests for cancer in the United States.Cancer Epidemiol. Biomarkers Prev.20172681192120810.1158/1055‑9965.EPI‑17‑021928515109
     [Google Scholar]
  56. National Cancer InstituteSEER is an authoritative source for cancer statistics in the United States.2017Available From https://seer.cancer.gov/
    [Google Scholar]
  57. MillerK.D. NogueiraL. MariottoA.B. Cancer treatment and survivorship statistics, 2019.CA Cancer J. Clin.201969536338510.3322/caac.2156531184787
     [Google Scholar]
  58. WardE. JemalA. CokkinidesV. Cancer disparities by race/ethnicity and socioeconomic status.CA Cancer J. Clin.2004542789310.3322/canjclin.54.2.7815061598
     [Google Scholar]
  59. AndrewA.S. ParkerS. AndersonJ.C. Risk factors for diagnosis of colorectal cancer at a late stage: A population-based study.J. Gen. Intern. Med.201833122100210510.1007/s11606‑018‑4648‑730284171
     [Google Scholar]
  60. El-ShamiK. OeffingerK.C. ErbN.L. American Cancer Society Colorectal Cancer Survivorship Care Guidelines.CA Cancer J. Clin.201565642745510.3322/caac.2128626348643
     [Google Scholar]
  61. Van CutsemE. CervantesA. AdamR. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.Ann. Oncol.20162781386142210.1093/annonc/mdw23527380959
     [Google Scholar]
  62. AlbandarM.H. ChoM.S. BaeS.U. KimN.K. Surgical management of extra-regional lymph node metastasis in colorectal cancer.Expert Rev. Anticancer Ther.201616550351310.1586/14737140.2016.116271826950286
     [Google Scholar]
  63. SalibasicM. PusinaS. BicakcicE. Colorectal cancer surgical treatment, our experience.Med. Arh.201973641241410.5455/medarh.2019.73.412‑41432082011
     [Google Scholar]
  64. LawrenceM.A. GoldbergS.M. Local excision for selected colorectal carcinomas.Baillieres Clin. Gastroenterol.19893372773710.1016/0950‑3528(89)90026‑22692739
     [Google Scholar]
  65. BledayR. BreenE. JessupM.J. BurgessA. SentovichS.M. SteeleG.Jr Prospective evaluation of local excision for small rectal cancers.Dis. Colon Rectum199740438839210.1007/BF022583819106685
     [Google Scholar]
  66. HeafnerT.A. GlasgowS.C. A critical review of the role of local excision in the treatment of early (T1 and T2) rectal tumors.J. Gastrointest. Oncol.20145534535225276407
     [Google Scholar]
  67. AlthumairiA.A. GearhartS.L. Local excision for early rectal cancer: Transanal endoscopic microsurgery and beyond.J. Gastrointest. Oncol.20156329630626029457
     [Google Scholar]
  68. FyockC.J. DraganovP.V. Colonoscopic polypectomy and associated techniques.World J. Gastroenterol.201016293630363710.3748/wjg.v16.i29.363020677334
     [Google Scholar]
  69. ZauberA.G. WinawerS.J. O’BrienM.J. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths.N. Engl. J. Med.2012366868769610.1056/NEJMoa110037022356322
     [Google Scholar]
  70. MossA. NalankilliK. Standardisation of polypectomy technique.Best Pract. Res. Clin. Gastroenterol.201731444745310.1016/j.bpg.2017.05.00728842055
     [Google Scholar]
  71. BentremD.J. OkabeS. WongW.D. T1 adenocarcinoma of the rectum: Transanal excision or radical surgery?Ann. Surg.2005242447247910.1097/01.sla.0000183355.94322.db16192807
     [Google Scholar]
  72. NashG.M. WeiserM.R. GuillemJ.G. Long-term survival after transanal excision of T1 rectal cancer.Dis. Colon Rectum200952457758210.1007/DCR.0b013e3181a0adbd19404055
     [Google Scholar]
  73. BuessG. KipfmüllerK. HackD. GrüssnerR. HeintzA. JungingerT. Technique of transanal endoscopic microsurgery.Surg. Endosc.198822717510.1007/BF007043563413659
     [Google Scholar]
  74. BuessG. Review: Transanal endoscopic microsurgery (TEM).J. R. Coll. Surg. Edinb.19933842392457693935
     [Google Scholar]
  75. JacobsM. VerdejaJ.C. GoldsteinH.S. Minimally invasive colon resection (laparoscopic colectomy).Surg. Laparosc. Endosc.1991131441501688289
     [Google Scholar]
  76. PhillipsE.H. FranklinM. CarrollB.J. FallasM.J. RamosR. RosenthalD. Laparoscopie Colectomy.Ann. Surg.1992216670371010.1097/00000658‑199212000‑000151466626
     [Google Scholar]
  77. AlvesA. PanisY. TrancartD. RegimbeauJ.M. PocardM. ValleurP. Factors associated with clinically significant anastomotic leakage after large bowel resection: Multivariate analysis of 707 patients.World J. Surg.200226449950210.1007/s00268‑001‑0256‑411910487
     [Google Scholar]
  78. KockN.G. DarleN. HulténL. KewenterJ. MyrvoldH. PhilipsonB. Ileostomy.Curr. Probl. Surg.197714815210.1016/S0011‑3840(77)80065‑8902503
     [Google Scholar]
  79. Allen-MershT.G. ThomsonJ.P.S. Surgical treatment of colostomy complications.Br. J. Surg.200575541641810.1002/bjs.18007505073390668
     [Google Scholar]
  80. LawW.L. ChuK.W. ChoiH.K. Total pelvic exenteration for locally advanced rectal cancer1.J. Am. Coll. Surg.20001901788310.1016/S1072‑7515(99)00229‑X10625236
     [Google Scholar]
  81. YangT.X. MorrisD.L. ChuaT.C. Pelvic exenteration for rectal cancer: A systematic review.Dis. Colon Rectum201356451953110.1097/DCR.0b013e31827a786823478621
     [Google Scholar]
  82. MastracciT.M. HendrenS. O’ConnorB. McLeodR.S. The impact of surgery for colorectal cancer on quality of life and functional status in the elderly.Dis. Colon Rectum200649121878188410.1007/s10350‑006‑0725‑917036203
     [Google Scholar]
  83. AkgülÖ. ÇetinkayaE. ErsözŞ. TezM. Role of surgery in colorectal cancer liver metastases.World J. Gastroenterol.201420206113612210.3748/wjg.v20.i20.611324876733
     [Google Scholar]
  84. TepperJ.E. Radiation therapy of colorectal cancer.Cancer198351S12Suppl.2528253410.1002/1097‑0142(19830615)51:12+<2528::AID‑CNCR2820511325>3.0.CO;2‑76406036
     [Google Scholar]
  85. WolpinB.M. MeyerhardtJ.A. MamonH.J. MayerR.J. Adjuvant treatment of colorectal cancer.CA Cancer J. Clin.200757316818510.3322/canjclin.57.3.16817507442
     [Google Scholar]
  86. WhiteJ. Carolan-ReesG. DaleM. Analysis of a national programme for selective internal radiation therapy for colorectal cancer liver metastases.Clin. Oncol. (R. Coll. Radiol.)2019311586610.1016/j.clon.2018.09.00230297164
     [Google Scholar]
  87. HoffmanK.E. HongT.S. ZietmanA.L. RussellA.H. External beam radiation treatment for rectal cancer is associated with a decrease in subsequent prostate cancer diagnosis.Cancer2008112494394910.1002/cncr.2324118098220
     [Google Scholar]
  88. BerbéeM. VerrijssenA.S. BuijsenJ. VerhaegenF. Van LimbergenE.J. The role of external beam and endoluminal radiation boosting in rectal cancer.Colorectal Cancer201981CRC0710.2217/crc‑2019‑0006
     [Google Scholar]
  89. AlektiarK.M. ZelefskyM.J. PatyP.B. High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer.Int. J. Radiat. Oncol. Biol. Phys.200048121922610.1016/S0360‑3016(00)00634‑910924992
     [Google Scholar]
  90. VuongT. DevicS. High-dose-rate pre-operative endorectal brachytherapy for patients with rectal cancer.J. Contemp. Brachytherapy20152218318810.5114/jcb.2015.5140226034500
     [Google Scholar]
  91. JeyarajahD.R. DoyleM.B.M. EspatN.J. Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: An evidence-based expert consensus algorithm.J. Gastrointest. Oncol.202011244346010.21037/jgo.2020.01.0932399284
     [Google Scholar]
  92. BoasF.E. BodeiL. SofocleousC.T. Radioembolization of colorectal liver metastases: Indications, technique, and outcomes.J. Nucl. Med.201758Suppl. 2104S111S10.2967/jnumed.116.18722928864605
     [Google Scholar]
  93. BirgissonH. PåhlmanL. GunnarssonU. GlimeliusB. Late adverse effects of radiation therapy for rectal cancer – a systematic overview.Acta Oncol.200746450451610.1080/0284186070134867017497318
     [Google Scholar]
  94. AuS. MarquezV. DonnellanF. Colorectal polyps in childhood cancer survivors treated with radiation therapy.Dig. Dis. Sci.20186392451245510.1007/s10620‑018‑5138‑929855768
     [Google Scholar]
  95. AllodjiR.S. HaddyN. Vu-BezinG. Risk of subsequent colorectal cancers after a solid tumor in childhood: Effects of radiation therapy and chemotherapy.Pediatr. Blood Cancer2019662e2749510.1002/pbc.2749530345604
     [Google Scholar]
  96. WolpinB.M. MayerR.J. Systemic treatment of colorectal cancer.Gastroenterology2008134512961310.e110.1053/j.gastro.2008.02.09818471507
     [Google Scholar]
  97. BerkeyF.J. Managing the adverse effects of radiation therapy.Am. Fam. Physician2010824381388, 39420704169
     [Google Scholar]
  98. MessersmithW.A. Systemic management of colorectal cancer.J. Natl. Compr. Canc. Netw.2017155S69970210.6004/jnccn.2017.007728515248
     [Google Scholar]
  99. YuI.S. CheungW.Y. Metastatic colorectal cancer in the era of personalized medicine: A more tailored approach to systemic therapy.Can. J. Gastroenterol. Hepatol.2018201811110.1155/2018/945075430519549
     [Google Scholar]
  100. WoodA.J.J. MoertelC.G. Chemotherapy for colorectal cancer.N. Engl. J. Med.1994330161136114210.1056/NEJM1994042133016088133857
     [Google Scholar]
  101. GoyleS. MaraveyasA. Chemotherapy for colorectal cancer.Dig. Surg.200522640141410.1159/00009144116479107
     [Google Scholar]
  102. KimJ.H. Chemotherapy for colorectal cancer in the elderly.World J. Gastroenterol.201521175158516610.3748/wjg.v21.i17.515825954089
     [Google Scholar]
  103. HammondW.A. SwaikaA. ModyK. Pharmacologic resistance in colorectal cancer: A review.Ther. Adv. Med. Oncol.201681578410.1177/175883401561453026753006
     [Google Scholar]
  104. CassidyS. SyedB.A. Colorectal cancer drugs market.Nat. Rev. Drug Discov.201716852552610.1038/nrd.2017.5928529321
     [Google Scholar]
  105. GengF. WangZ. YinH. YuJ. CaoB. Molecular targeted drugs and treatment of colorectal cancer: Recent progress and future perspectives.Cancer Biother. Radiopharm.201732514916010.1089/cbr.2017.221028622036
     [Google Scholar]
  106. BergD. Managing the side effects of chemotherapy for colorectal cancer.Semin. Oncol.1998255Suppl. 1153599786317
     [Google Scholar]
  107. SchuellB. GruenbergerT. KornekG.V. Side effects during chemotherapy predict tumour response in advanced colorectal cancer.Br. J. Cancer200593774474810.1038/sj.bjc.660278316160693
     [Google Scholar]
  108. WeeksJ.C. CatalanoP.J. CroninA. Patients’ expectations about effects of chemotherapy for advanced cancer.N. Engl. J. Med.2012367171616162510.1056/NEJMoa120441023094723
     [Google Scholar]
  109. SeeberA. GastlG. Targeted therapy of colorectal cancer.Oncol. Res. Treat.2016391279680210.1159/00045302727889786
     [Google Scholar]
  110. LieuC.H. CorcoranR.B. OvermanM.J. Integrating biomarkers and targeted therapy into colorectal cancer management.Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet20193920715
     [Google Scholar]
  111. MacarullaT. CasadoE. RamosF.J. ValverdeC. TaberneroJ. Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer.Onkologie20062939910516514271
     [Google Scholar]
  112. MausM.K.H. HannaD.L. StephensC.L. Distinct gene expression profiles of proximal and distal colorectal cancer: Implications for cytotoxic and targeted therapy.Pharmacogenomics J.201515435436210.1038/tpj.2014.7325532759
     [Google Scholar]
  113. LopezA. HaradaK. VasilakopoulouM. ShanbhagN. AjaniJ.A. Targeting angiogenesis in colorectal carcinoma.Drugs2019791637410.1007/s40265‑018‑1037‑930617958
     [Google Scholar]
  114. KhanK. ValeriN. DearmanC. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution.Crit. Rev. Oncol. Hematol.201914315316310.1016/j.critrevonc.2019.09.00131678702
     [Google Scholar]
  115. MizukamiT. IzawaN. NakajimaT.E. SunakawaY. Targeting EGFR and RAS/RAF signaling in the treatment of metastatic colorectal cancer: From current treatment strategies to future perspectives.Drugs201979663364510.1007/s40265‑019‑01113‑030968289
     [Google Scholar]
  116. NovellasdemuntL. AntasP. LiV.S.W. Targeting Wnt signaling in colorectal cancer. A review in the theme: Cell Signaling: Proteins, pathways and mechanisms.Am. J. Physiol. Cell Physiol.20153098C511C52110.1152/ajpcell.00117.201526289750
     [Google Scholar]
  117. LiuY. WanW. LiY. ZhouG. LiuX. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.Oncotarget2017847181720010.18632/oncotarget.1274227769061
     [Google Scholar]
  118. FergusonF.M. GrayN.S. Kinase inhibitors: The road ahead.Nat. Rev. Drug Discov.201817535337710.1038/nrd.2018.2129545548
     [Google Scholar]
  119. MarkmanJ.L. ShiaoS.L. Impact of the immune system and immunotherapy in colorectal cancer.J. Gastrointest. Oncol.20156220822325830040
     [Google Scholar]
  120. BasileD. GarattiniS.K. BonottoM. Immunotherapy for colorectal cancer: Where are we heading?Expert Opin. Biol. Ther.201717670972110.1080/14712598.2017.131540528375039
     [Google Scholar]
  121. TarimanJ.D. Changes in cancer treatment.Nurs. Clin. North Am.2017521658110.1016/j.cnur.2016.10.00428189167
     [Google Scholar]
  122. JacobsJ. SmitsE. LardonF. PauwelsP. DeschoolmeesterV. Immune checkpoint modulation in colorectal cancer: What’s new and what to expect.J. Immunol. Res.2015201511610.1155/2015/15803826605342
     [Google Scholar]
  123. PassardiA. CanaleM. ValgiustiM. UliviP. Immune checkpoints as a target for colorectal cancer treatment.Int. J. Mol. Sci.2017186132410.3390/ijms1806132428635639
     [Google Scholar]
  124. KöhneC.H. Successes and limitations of targeted cancer therapy in colon cancer.Prog. Tumor Res.201441365010.1159/00035643624727985
     [Google Scholar]
  125. ZhangB. FangC. DengD. XiaL. Research progress on common adverse events caused by targeted therapy for colorectal cancer (Review).Oncol. Lett.2018161273310.3892/ol.2018.865129928383
     [Google Scholar]
  126. EdwardsP. MonahanK.J. Diagnosis and management of Lynch syndrome.Frontline Gastroenterol.202213e1e80e8710.1136/flgastro‑2022‑10212335812033
     [Google Scholar]
  127. DeyA. MitraA. PathakS. Recent advancements, limitations, and future perspectives of the use of personalized medicine in treatment of colon cancer.Technol. Cancer Res. Treat.20232210.1177/1533033823117840337248615
     [Google Scholar]
  128. KhanS.Z. LengyelC.G. Challenges in the management of colorectal cancer in low- and middle-income countries.Cancer Treat. Res. Commun.20233510070510.1016/j.ctarc.2023.10070537060879
     [Google Scholar]
  129. RosenL.S. JacobsI.A. BurkesR.L. Bevacizumab in colorectal cancer: Current role in treatment and the potential of biosimilars.Target. Oncol.201712559961010.1007/s11523‑017‑0518‑128801849
     [Google Scholar]
  130. XieY.H. ChenY.X. FangJ.Y. Comprehensive review of targeted therapy for colorectal cancer.Signal Transduct. Target. Ther.2020512210.1038/s41392‑020‑0116‑z32296018
     [Google Scholar]
  131. RougierP. BugatR. DouillardJ.Y. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.J. Clin. Oncol.199715125126010.1200/JCO.1997.15.1.2518996150
     [Google Scholar]
  132. YaffeP.B. Power CoombsM.R. DoucetteC.D. WalshM. HoskinD.W. Piperine, an alkaloid from black pepper, inhibits growth of human colon cancer cells via G1 arrest and apoptosis triggered by endoplasmic reticulum stress.Mol. Carcinog.201554101070108510.1002/mc.2217624819444
     [Google Scholar]
  133. BonchevaV. BonneyS.A. BrooksS.E. New targets for the immunotherapy of colon cancer—does reactive disease hold the answer?Cancer Gene Ther.201320315716810.1038/cgt.2013.523492821
     [Google Scholar]
  134. KrishnamurthyN. KurzrockR. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors.Cancer Treat. Rev.201862506010.1016/j.ctrv.2017.11.00229169144
     [Google Scholar]
  135. TiwariA. SarafS. VermaA. PandaP.K. JainS.K. Novel targeting approaches and signaling pathways of colorectal cancer: An insight.World J. Gastroenterol.201824394428443510.3748/wjg.v24.i39.442830357011
     [Google Scholar]
  136. FerraraN. GerberH.P. LeCouterJ. The biology of VEGF and its receptors.Nat. Med.20039666967610.1038/nm0603‑66912778165
     [Google Scholar]
  137. SaharinenP. EklundL. PulkkiK. BonoP. AlitaloK. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis.Trends Mol. Med.201117734736210.1016/j.molmed.2011.01.01521481637
     [Google Scholar]
  138. GoelH.L. MercurioA.M. VEGF targets the tumour cell.Nat. Rev. Cancer2013131287188210.1038/nrc362724263190
     [Google Scholar]
  139. FolkmanJ. Role of angiogenesis in tumor growth and metastasis.Semin. Oncol.2002296Suppl. 16151810.1016/S0093‑7754(02)70065‑112516034
     [Google Scholar]
  140. TakahashiH. ShibuyaM. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.Clin. Sci. (Lond.)2005109322724110.1042/CS2004037016104843
     [Google Scholar]
  141. LeeY.J. KarlD.L. MaduekweU.N. Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment.Cancer Res.201070218357836710.1158/0008‑5472.CAN‑10‑113820978198
     [Google Scholar]
  142. RiechelmannR. GrotheyA. Antiangiogenic therapy for refractory colorectal cancer: Current options and future strategies.Ther. Adv. Med. Oncol.20179210612610.1177/175883401667670328203302
     [Google Scholar]
  143. KongD.H. KimM. JangJ. NaH.J. LeeS. A review of anti-angiogenic targets for monoclonal antibody cancer therapy.Int. J. Mol. Sci.2017188178610.3390/ijms1808178628817103
     [Google Scholar]
  144. TebbuttN. PedersenM.W. JohnsT.G. Targeting the ERBB family in cancer: Couples therapy.Nat. Rev. Cancer201313966367310.1038/nrc355923949426
     [Google Scholar]
  145. ArteagaC.L. EngelmanJ.A. ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics.Cancer Cell201425328230310.1016/j.ccr.2014.02.02524651011
     [Google Scholar]
  146. VecchioneL. JacobsB. NormannoN. CiardielloF. TejparS. EGFR-targeted therapy.Exp. Cell Res.2011317192765277110.1016/j.yexcr.2011.08.02121925171
     [Google Scholar]
  147. WangZ. ErbB receptors and cancer.Methods Mol. Biol.2017165233510.1007/978‑1‑4939‑7219‑7_128791631
     [Google Scholar]
  148. RoskoskiR.Jr Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.Pharmacol. Res.201913939541110.1016/j.phrs.2018.11.01430500458
     [Google Scholar]
  149. YaromN. JonkerD.J. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.Discov. Med.201111579510521356164
     [Google Scholar]
  150. SeshacharyuluP. PonnusamyM.P. HaridasD. JainM. GantiA.K. BatraS.K. Targeting the EGFR signaling pathway in cancer therapy.Expert Opin. Ther. Targets2012161153110.1517/14728222.2011.64861722239438
     [Google Scholar]
  151. JonkerD.J. O’CallaghanC.J. KarapetisC.S. Cetuximab for the treatment of colorectal cancer.N. Engl. J. Med.2007357202040204810.1056/NEJMoa07183418003960
     [Google Scholar]
  152. DouillardJ.Y. SienaS. CassidyJ. Final results from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.Ann. Oncol.20142571346135510.1093/annonc/mdu14124718886
     [Google Scholar]
  153. SmythL.A. CollinsI. Measuring and interpreting the selectivity of protein kinase inhibitors.J. Chem. Biol.20092313115110.1007/s12154‑009‑0023‑919568781
     [Google Scholar]
  154. García-ArandaM. RedondoM. Targeting receptor kinases in colorectal cancer.Cancers (Basel)201911443310.3390/cancers1104043330934752
     [Google Scholar]
  155. ShenY. WangJ. HanX. Effectors of epidermal growth factor receptor pathway: The genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.PLoS One2013812e8162810.1371/journal.pone.008162824339949
     [Google Scholar]
  156. WilsonC.Y. ToliasP. Recent advances in cancer drug discovery targeting RAS.Drug Discov. Today201621121915191910.1016/j.drudis.2016.08.00227506872
     [Google Scholar]
  157. ChuangS.C. HuangC.W. ChenY.T. Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver only and lung only metastases.Oncol. Lett.20202032119213010.3892/ol.2020.1179532782529
     [Google Scholar]
  158. KyriakisJ.M. AppH. ZhangX. Raf-1 activates MAP kinase-kinase.Nature1992358638541742110.1038/358417a01322500
     [Google Scholar]
  159. DaviesH. BignellG.R. CoxC. Mutations of the BRAF gene in human cancer.Nature2002417689294995410.1038/nature0076612068308
     [Google Scholar]
  160. MalumbresM. BarbacidM. RAS oncogenes: The first 30 years.Nat. Rev. Cancer20033645946510.1038/nrc109712778136
     [Google Scholar]
  161. VenderboschS. NagtegaalI.D. MaughanT.S. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.Clin. Cancer Res.201420205322533010.1158/1078‑0432.CCR‑14‑033225139339
     [Google Scholar]
  162. BarrasD. BRAF mutation in colorectal cancer: An update.Biomark Cancer20157s1Suppl. 1S2524810.4137/BIC.S2524826396549
     [Google Scholar]
  163. CorcoranR.B. AndréT. AtreyaC.E. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF V600E-mutant colorectal cancer.Cancer Discov.20188442844310.1158/2159‑8290.CD‑17‑122629431699
     [Google Scholar]
  164. RichmanS.D. SouthwardK. ChambersP. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.J. Pathol.2016238456257010.1002/path.467926690310
     [Google Scholar]
  165. GreallyM. KellyC.M. CercekA. HER2: An emerging target in colorectal cancer.Curr. Probl. Cancer201842656057110.1016/j.currproblcancer.2018.07.00130100092
     [Google Scholar]
  166. La SalviaA. Lopez-GomezV. Garcia-CarboneroR. HER2-targeted therapy: An emerging strategy in advanced colorectal cancer.Expert Opin. Investig. Drugs2019281293810.1080/13543784.2019.155558330513002
     [Google Scholar]
  167. MaoC. YangZ.Y. HuX.F. ChenQ. TangJ.L. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis.Ann. Oncol.20122361518152510.1093/annonc/mdr46422039088
     [Google Scholar]
  168. NagataY. LanK.H. ZhouX. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.Cancer Cell20046211712710.1016/j.ccr.2004.06.02215324695
     [Google Scholar]
  169. Laurent-PuigP. CayreA. ManceauG. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.J. Clin. Oncol.200927355924593010.1200/JCO.2008.21.679619884556
     [Google Scholar]
  170. ZhangJ. RobertsT.M. ShivdasaniR.A. Targeting PI3K signaling as a therapeutic approach for colorectal cancer.Gastroenterology20111411506110.1053/j.gastro.2011.05.01021723986
     [Google Scholar]
  171. PanduranganA.K. Potential targets for prevention of colorectal cancer: A focus on PI3K/Akt/mTOR and Wnt pathways.J Cancer Prev APJCP20131442201220523725112
     [Google Scholar]
  172. WeiS.C. DuffyC.R. AllisonJ.P. Fundamental mechanisms of immune checkpoint blockade therapy.Cancer Discov.2018891069108610.1158/2159‑8290.CD‑18‑036730115704
     [Google Scholar]
  173. JácomeA.A. EngC. Role of immune checkpoint inhibitors in the treatment of colorectal cancer: Focus on nivolumab.Expert Opin. Biol. Ther.201919121247126310.1080/14712598.2019.168063631642347
     [Google Scholar]
  174. YaghoubiN. SoltaniA. GhazviniK. HassanianS.M. HashemyS.I. PD-1/PD-L1 blockade as a novel treatment for colorectal cancer.Biomed. Pharmacother.201911031231810.1016/j.biopha.2018.11.10530522017
     [Google Scholar]
  175. PayandehZ. KhaliliS. SomiM.H. PD‐1/PD‐L1‐dependent immune response in colorectal cancer.J. Cell. Physiol.20202357-85461547510.1002/jcp.2949431960962
     [Google Scholar]
  176. American Association for Cancer Research. PD-1 inhibitor bests chemo for colorectal cancer.Cancer Discov.2020107OF2
     [Google Scholar]
  177. ShanT. ChenS. WuT. YangY. LiS. ChenX. PD-L1 expression in colon cancer and its relationship with clinical prognosis.Int. J. Clin. Exp. Pathol.20191251764176931933995
     [Google Scholar]
  178. TarhiniA. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: The underlying mechanisms and clinical management.Scientifica (Cairo)2013201311910.1155/2013/85751924278787
     [Google Scholar]
  179. RotteA. Combination of CTLA-4 and PD-1 blockers for treatment of cancer.J. Exp. Clin. Cancer Res.201938125510.1186/s13046‑019‑1259‑z31196207
     [Google Scholar]
  180. DenoeudJ. MoserM. Role of CD27/CD70 pathway of activation in immunity and tolerance.J. Leukoc. Biol.201089219520310.1189/jlb.061035120699361
     [Google Scholar]
  181. ClausC. RietherC. SchürchC. MatterM.S. HilmenyukT. OchsenbeinA.F. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth.Cancer Res.201272143664367610.1158/0008‑5472.CAN‑11‑279122628427
     [Google Scholar]
  182. JacobsJ. DeschoolmeesterV. ZwaenepoelK. CD70: An emerging target in cancer immunotherapy.Pharmacol. Ther.201515511010.1016/j.pharmthera.2015.07.00726213107
     [Google Scholar]
  183. InoueS. ItoH. TsunodaT. CD70 expression in tumor-associated fibroblasts predicts worse survival in colorectal cancer patients.Virchows Arch.2019475442543410.1007/s00428‑019‑02565‑130980190
     [Google Scholar]
  184. Sánchez-GundínJ. Fernández-CarballidoA.M. Martínez-ValdiviesoL. Barreda-HernándezD. Torres-SuárezA.I. New trends in the therapeutic approach to metastatic colorectal cancer.Int. J. Med. Sci.201815765966510.7150/ijms.2445329910669
     [Google Scholar]
  185. KeumN. GiovannucciE. Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies.Nat. Rev. Gastroenterol. Hepatol.2019161271373210.1038/s41575‑019‑0189‑831455888
     [Google Scholar]
  186. LabiancaR. NordlingerB. BerettaG.D. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann. Oncol.201324Suppl. 6vi64vi7210.1093/annonc/mdt35424078664
     [Google Scholar]
  187. KuipersE.J. GradyW.M. LiebermanD. Colorectal cancer.Nat. Rev. Dis. Primers2015111506510.1038/nrdp.2015.6527189416
     [Google Scholar]
  188. MartiniG. TroianiT. CardoneC. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.World J. Gastroenterol.201723264675468810.3748/wjg.v23.i26.467528765689
     [Google Scholar]
  189. BrownK.G.M. SolomonM.J. MahonK. O’ShannassyS. Management of colorectal cancer.BMJ2019366l456110.1136/bmj.l456131439545
     [Google Scholar]
  190. MessersmithWA NCCN Guidelines Updates: Management of Metastatic Colorectal Cancer. J Natl Compr Canc Netw 2019175.559960131117039
     [Google Scholar]
/content/journals/ccand/10.2174/012212697X308365240529100442
Loading
Current Perspective and Treatment Strategies in Targeted Therapy for Colorectal Cancer
Clinical Cancer Drugs 10, E110724231870 (2024); https://doi.org/10.2174/012212697X308365240529100442
/content/journals/ccand/10.2174/012212697X308365240529100442
/content/journals/ccand/10.2174/012212697X308365240529100442
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cells; chemotherapy; Colorectal cancer (CRC); drug target; molecular mechanisms; radiotheraphy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test